Question 1405 — human blood and organs

Summary

Ms. Élisabeth Toutut-Picard draws the attention of the Minister of Solidarity and Health to the traceability of plasma used in the composition of blood-derived medicines (MDS) sold in France. In France, blood donation is historically based on the principles of volunteerism and free donation. Until 2014, plasma for therapeutic purposes was considered a labile blood product (PSL) manufactured by the French establishment. blood (EFS). The March 13, 2014 ruling of the Court of Justice of the European Union transformed it into a medicine, opening its production to multinationals. French legislation (in particular article 71 of the social security financing law for 2015) has incorporated the European decision, while requiring that MDS entering our territory be manufactured from “ethical” plasma, resulting from voluntary and unpaid donation. Gold multinationals would collect plasma mainly in the United States, where this activity is paid. She asks him if the Government plans to supplement the law in order to guarantee the traceability of plasma introduced into France, compliance with regulations and health safety.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.